与此同时，我国加快推进体制机制改革，高校院所科技成果"不想转、不敢转、不会转"难题逐步破 解。完善科技成果转化服务体系，科技成果转化生态进一步优化。加快构建与科技创新相适应的科技金 融体制，赋能科技成果转化取得积极成效。 报告也指出了我国科技成果转化工作存在的问题，包括高质量科技成果供给不足、企业科技成果转 化主体作用发挥不够、科技成果转化体制机制还存在障碍、科技成果转化专业化服务能力不强、科技金 融支持成果转化效能亟待加强。 根据报告，下一步，我国将加快制定相关政策措施，加强原始创新和关键技术攻关，推动科技创新 和产业创新深度融合，进一步深化科技成果转化机制改革，提升科技成果转化服务能力，构建覆盖科技 成果转化全链条的金融服务体系，推动我国科技成果转化工作再上新台阶，有力支撑新质生产力发展。 新华社北京12月22日电（记者 温竞华）国务院关于促进科技成果转化工作情况的报告12月22日提 请十四届全国人大常委会第十九次会议审议。报告显示，"十四五"以来，我国科技成果转化实现量质齐 升，有效推动科技成果向现实生产力转化。 报告显示，2020年到2024年，全国技术合同成交金额从2.83万亿元增长到6.84万亿元 ...

（来源：中国妇女报） 转自：中国妇女报 中国妇女报全媒体记者王蓓 发自合肥 12月19日，安徽省合肥市包河区召开女企业家协会第二届会员大 会并启动"新程"赋能行动计划（2026—2030年）。会议审议通过了包河区女企业家协会章程、会费管理 办法和选举办法等，选举产生了包河区女企业家协会第二届理事会和班子成员。美而特智能后勤服务有 限公司董事长常征当选新一届会长。包河区女企业家协会党支部、妇联同步成立并揭牌。 合肥市妇联党组书记、主席束红英希望协会帮助会员开阔视野、提升战略思维和管理能力，加强与其他 优秀女企业家组织的交流合作，融入更大发展格局，在稳定就业、关爱员工等方面主动作为，展现新时 代女企业家的良好形象。 全区各行业110余名优秀女企业家代表参加会议。 此次换届吸纳了全区119个会员单位，涵盖人工智能、文化创意、生物科技等多个行业领域。据悉，围 绕赋能行动计划的"三百"目标，还将实施"领航""融智""聚势""共益"四大行动，为包河区高质量发展注 入澎湃的巾帼动能。 包河区委书记周天斌出席会议，希望区女企协提高政治站位，以创新理论引领行动，以大局大势引领方 向，以党建品牌引领发展。把握风口机遇，赋能企业成 ...

随着我国综合国力不断增强，高等教育国际化水平不断提高，我国已从传统的留学输出国转变为全球重 要的留学目的国，来华留学生规模也在急剧扩大。观察留学教育的发展历程，国际学生来华留学规模持 续扩大，留学层次不断提高，其专业选择也经历了从语言进修为主到学历教育为主，从传统优势学科到 多元前沿领域的深刻变迁。国际学生的选择既体现了对中国优势领域的认可，也反映了个人职业发展的 考量。 多元前沿领域、STEM专业和新兴交叉学科成为国际学生新选择 国际学生来华选择的专业领域经历了明显的变迁过程。早期来华留学生主要集中在语言文化类专业，以 学习汉语和中国传统文化为主要目的。随着中国高等教育质量的提升以及国际影响力的增强，留学生的 专业选择逐步扩展到医学、工程、商科等多个领域。值得关注的是，在科技发展与产业变革加速的背景 下，人工智能、大数据、生物科技、可持续能源等前沿领域正深刻重塑全球产业格局，对高端人才需求 迫切。在这一全球趋势影响下，来华留学生也开始关注并选择这些新兴专业，使专业选择更加多元化和 前沿化。 尽管全球范围内商科与经济学仍占留学申请的首位，但STEM专业（科学、技术、工程、数学）的全球 趋势正在增强，这一趋势也 ...

Group 1 - The core viewpoint of the article highlights that the Hong Kong stock market (HKEX) is set to become the "global fundraising king" in 2025, with significant growth in IPO activities and fundraising amounts [1][2][3] - As of December 18, 2023, 102 companies have listed on the Hong Kong stock market, raising a net amount of HKD 238.2 billion, which represents a 246% increase compared to the same period last year [2][3] - Ernst & Young (EY) forecasts that the total fundraising amount for HKEX could reach USD 36 billion in 2025, making it the highest globally [3][5] Group 2 - The "new economy" sectors, including industrial engineering, gold and precious metals, automotive, pharmaceuticals, and biotechnology, have collectively raised over HKD 130 billion [1][3] - The IPO boom has led to a dynamic balance in the market, with 27 companies privatizing and delisting, while 30 companies have had their listings canceled [4] - The average daily trading volume in the first half of 2025 is expected to surge to HKD 240.2 billion, reflecting a 118% year-on-year increase [7] Group 3 - The number of pending IPO applications has exceeded 300, creating a "bottleneck" in the review process, raising concerns about the quality of submitted documents [1][13] - The market is also worried that the concentrated issuance of new stocks may divert liquidity from the secondary market [13][14] - Despite the challenges, the overall risk is considered manageable, with expectations for a wave of lock-up expirations in 2026 following the active IPO activities of 2025 [1][16] Group 4 - The influx of mainland companies seeking to list in Hong Kong is a key driver behind the market's resurgence, with significant IPOs from companies like CATL and Zijin Mining [9][11] - Policy improvements, such as the establishment of fast-track listing channels for tech companies, have contributed to the current IPO boom [12] - The introduction of the Hong Kong Stock Exchange Technology 100 Index aims to enhance the market's image and support innovation-driven enterprises [12]

Core Insights - The Hong Kong stock market has seen a significant increase in IPO activities, with 102 companies listed and a net fundraising amount of HKD 238.2 billion, representing a 246% increase compared to the same period last year [1][2] - Ernst & Young predicts that the Hong Kong Stock Exchange (HKEX) will become the world's largest fundraising exchange in 2025, with an expected fundraising amount of USD 36 billion [1][2] - The "new economy" sectors, including industrial engineering, gold and precious metals, automotive, pharmaceuticals, and biotechnology, have collectively raised over HKD 130 billion [1][2] IPO Activity - As of December 18, 2023, the number of IPOs in Hong Kong has surpassed last year's total of 73, with a current count of 102 [2] - The top five sectors by fundraising amount are industrial engineering (HKD 31.98 billion), gold and precious metals (HKD 29.49 billion), automotive (HKD 25.82 billion), pharmaceuticals and biotechnology (HKD 23.53 billion), and software services [2][6] - The IPO boom has led to a dynamic balance in the market, with 27 companies privatized and 30 companies delisted this year [2] Market Dynamics - The average daily trading volume in the first half of 2025 is expected to reach HKD 240.2 billion, a 118% increase year-on-year, indicating a significant recovery in market activity and liquidity [3] - The enthusiasm for IPOs has resulted in a high percentage of new stocks performing well, with 76 out of 102 new listings seeing their stock prices rise [4] - A record-breaking subscription rate was observed, with one GEM-listed company achieving a subscription multiple of 11,465 times [4] Listing Drivers - The influx of large IPOs from mainland China has been a key driver for the rise of the Hong Kong stock market [5][6] - The average fundraising scale of the top ten IPOs has increased by 137% compared to 2024, with major contributions from companies like CATL and Zijin Mining [6][7] - The number of pending IPO applications has surged to over 319, covering various sectors including AI and biotechnology [10][11] Regulatory Environment - The Hong Kong Stock Exchange has implemented several reforms to facilitate the listing process, including the establishment of a fast-track listing channel for tech companies [9] - The introduction of the Hong Kong Stock Exchange Technology 100 Index aims to enhance the market's image and support innovation-driven enterprises [9] Future Outlook - The IPO market is expected to remain active in 2026, with a focus on A+H listings and the return of Chinese concept stocks [14] - Despite potential challenges from a wave of lock-up expirations, the overall risk is considered manageable [14][15] - The macroeconomic environment, including anticipated interest rate cuts by the Federal Reserve, may provide additional support for the market [16]

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 12月16日，港股通生物科技ETF（159102）跌1.81%，成交额2222.11万元。当日份额增加150.00万份， 最新份额为8.58亿份，近20个交易日份额减少550.00万份。最新资产净值计算值为7.03亿元。 港股通生物科技ETF（159102）业绩比较基准为恒生生物科技指数收益率(经汇率调整)，管理人为华安 基金管理有限公司，基金经理为倪斌，成立（2025-09-05）以来回报为-18.03%，近一个月回报 为-11.11%。 来源：新浪基金∞工作室 ...

Group 1 - The pharmaceutical sector experienced narrow fluctuations, with the Hang Seng Innovative Drug Index down by 0.1%, while other indices such as the CSI Hong Kong Pharmaceutical and Health Comprehensive Index and the CSI Biotech Theme Index both rose by 0.1% [1] - The CSI Innovative Drug Industry Index saw an increase of 0.2%, indicating a positive trend in innovative drug stocks [1] - Recent fund inflows into ETFs indicate continued investment interest, with the Hang Seng Innovative Drug ETF and Pharmaceutical ETF receiving net inflows of 97 million yuan and 370 million yuan respectively over the past week [1] Group 2 - The index focuses on leading stocks in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other pharmaceutical sectors [3] - The Innovative Drug ETF tracks the CSI Innovative Drug Industry Index, which includes no more than 50 companies primarily engaged in innovative drug research and development [4][5] - The Biotech ETF tracks the CSI Biotech Theme Index, which consists of up to 50 companies involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [6][8] Group 3 - The CSI Biotech Theme Index recorded a slight increase of 0.1% at midday [7] - The CSI Pharmaceutical and Health Industry Index, which includes companies from the CSI 300 Index in the pharmaceutical sector, also rose by 0.1% [12][13]

天眼查App显示，近日，厦门初代汉方生物科技有限公司成立，法定代表人为钟粤，注册资本600万人 民币，经营范围为一般项目：生物基材料技术研发；技术推广服务；食品添加剂销售；食品销售（仅销 售预包装食品，不含酒）；塑料包装箱及容器制造；包装服务；食品、酒、饮料及茶生产专用设备制 造；包装专用设备制造；包装专用设备销售。（除依法须经批准的项目外，凭营业执照依法自主开展经 营活动）。 ...

Market Overview - The A-share pharmaceutical sector opened lower and continued to decline, while the Hong Kong pharmaceutical sector showed signs of recovery in the afternoon, with a significant narrowing of losses [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 0.8%, the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 0.9%, the China Securities Biotechnology Theme Index dropped by 1.5%, the CSI 300 Pharmaceutical and Health Index declined by 1.7%, and the China Securities Innovative Drug Industry Index fell by 1.9% [1] Fund Activity - Despite the market downturn, there was a counter-trend investment with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of approximately 20 million units throughout the day [1]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking a significant milestone in its index and data business development, reflecting a fundamental shift in the market structure towards technology as a key sector [1][2]. Group 1: Introduction of the Technology 100 Index - The Technology 100 Index tracks the performance of 100 of the largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1]. - The index is designed to meet the investment needs of both international and mainland Chinese investors, as all constituent stocks are eligible for the Stock Connect program [1]. Group 2: Market Trends and Investor Demand - There has been a notable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [2]. - Data indicates that the market structure has transitioned from traditional industries to being dominated by technology companies, with the market capitalization of technology stocks in the Stock Connect increasing from approximately 10% in 2014 to about 40% by 2025 [2]. Group 3: Differentiation from Existing Indices - The Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 200 million HKD [3]. - This broader coverage aims to cater to diverse investor needs, enhancing the overall attractiveness of the market [4]. Group 4: Accessibility and Future Developments - All constituent stocks of the Technology 100 Index must meet the eligibility criteria for Stock Connect, ensuring ease of access for mainland fund companies [5]. - The index has a mechanism for rapid inclusion of representative new stocks, allowing it to reflect market dynamics promptly [5]. - Future plans for the HKEX include the introduction of more indices, including thematic indices, to meet growing investor demand [5].